Insider Selling: Teleflex Incorporated (TFX) CEO Sells 2,000 Shares of Stock
Teleflex Incorporated (NYSE:TFX) CEO Benson Smith sold 2,000 shares of Teleflex stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $258.10, for a total value of $516,200.00. Following the sale, the chief executive officer now directly owns 76,634 shares of the company’s stock, valued at approximately $19,779,235.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Teleflex Incorporated (NYSE:TFX) traded down $1.23 during mid-day trading on Tuesday, reaching $251.75. The company had a trading volume of 341,516 shares, compared to its average volume of 260,808. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72. The stock has a market capitalization of $11,450.00, a PE ratio of 32.83, a P/E/G ratio of 2.27 and a beta of 1.09. Teleflex Incorporated has a 52 week low of $151.22 and a 52 week high of $271.23.
Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.11. The company had revenue of $534.70 million during the quarter, compared to analysts’ expectations of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. Teleflex’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period last year, the business earned $1.80 earnings per share. research analysts anticipate that Teleflex Incorporated will post 8.35 EPS for the current year.
A number of equities research analysts recently commented on TFX shares. Jefferies Group lifted their target price on Teleflex from $253.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, September 8th. Needham & Company LLC lifted their target price on Teleflex from $228.00 to $237.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. Zacks Investment Research upgraded Teleflex from a “hold” rating to a “buy” rating and set a $232.00 price target for the company in a research report on Friday, September 1st. Deutsche Bank reiterated a “buy” rating and set a $238.00 price target (up from $220.00) on shares of Teleflex in a research report on Wednesday, August 9th. Finally, Stephens reiterated a “buy” rating and set a $270.00 price target (up from $230.00) on shares of Teleflex in a research report on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $274.44.
Several institutional investors have recently bought and sold shares of TFX. Toronto Dominion Bank increased its position in shares of Teleflex by 14.5% in the second quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after buying an additional 70 shares in the last quarter. Advisory Services Network LLC increased its position in shares of Teleflex by 933.8% in the second quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock valued at $172,000 after buying an additional 747 shares in the last quarter. Cornerstone Capital Management Holdings LLC. purchased a new stake in shares of Teleflex in the second quarter valued at approximately $175,000. Calamos Advisors LLC purchased a new stake in shares of Teleflex in the second quarter valued at approximately $206,000. Finally, Advisor Partners LLC purchased a new stake in shares of Teleflex in the second quarter valued at approximately $212,000. Institutional investors and hedge funds own 89.31% of the company’s stock.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.